Clinical trial
Single Ascending Dose Study of SRA-444 in Healthy Subjects
NCT00452504 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00452504 |
|---|---|
| Title | Single Ascending Dose Study of SRA-444 in Healthy Subjects |
| Official title | Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SRA-444 Administered Orally to Healthy Adult Subjects |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Drug |
| Interventions | SRA-444 |
| Enrollment | 64 |
| Start date | Feb 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Mar 27, 2007 |
| Last update posted | Dec 5, 2007 |
| Countries | Netherlands |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: